ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Primary Biliary Cholangitis Treatment Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-27U5706
Home | Market Reports | Health| Health Conditions
Global Primary Biliary Cholangitis Treatment Market Insights and Forecast to 2028
BUY CHAPTERS

Global Primary Biliary Cholangitis Treatment Market Research Report 2025

Code: QYRE-Auto-27U5706
Report
September 2025
Pages:75
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Bristol–Myers Squibb
Pfizer Inc
GlaxoSmithKline PLC
Teva Pharmaceutical
Retrophin
Lumena Pharmaceuticals
Intercept Pharmaceuticals

Primary Biliary Cholangitis Treatment Market Size

The global market for Primary Biliary Cholangitis Treatment was valued at US$ 846 million in the year 2024 and is projected to reach a revised size of US$ 1154 million by 2031, growing at a CAGR of 4.6% during the forecast period.

Primary Biliary Cholangitis Treatment Market

Primary Biliary Cholangitis Treatment Market

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. There"s no cure for primary biliary cholangitis, but medications are available to help slow the progression of the disease and prevent complications. Options include: Ursodeoxycholic acid (UDCA) and Obeticholic acid (Ocaliva).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Primary Biliary Cholangitis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Biliary Cholangitis Treatment.
The Primary Biliary Cholangitis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Primary Biliary Cholangitis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Biliary Cholangitis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Primary Biliary Cholangitis Treatment Market Report

Report Metric Details
Report Name Primary Biliary Cholangitis Treatment Market
Accounted market size in year US$ 846 million
Forecasted market size in 2031 US$ 1154 million
CAGR 4.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Ursodeoxycholic Acid (UDCA)
  • Obeticholic Acid (Ocaliva)
Segment by Application
  • Hospitals
  • Clinics
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Teva Pharmaceutical, Retrophin, Lumena Pharmaceuticals, Intercept Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Primary Biliary Cholangitis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Primary Biliary Cholangitis Treatment Market growing?

Ans: The Primary Biliary Cholangitis Treatment Market witnessing a CAGR of 4.6% during the forecast period 2025-2031.

What is the Primary Biliary Cholangitis Treatment Market size in 2031?

Ans: The Primary Biliary Cholangitis Treatment Market size in 2031 will be US$ 1154 million.

Who are the main players in the Primary Biliary Cholangitis Treatment Market report?

Ans: The main players in the Primary Biliary Cholangitis Treatment Market are Novartis, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Teva Pharmaceutical, Retrophin, Lumena Pharmaceuticals, Intercept Pharmaceuticals

What are the Application segmentation covered in the Primary Biliary Cholangitis Treatment Market report?

Ans: The Applications covered in the Primary Biliary Cholangitis Treatment Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Primary Biliary Cholangitis Treatment Market report?

Ans: The Types covered in the Primary Biliary Cholangitis Treatment Market report are Ursodeoxycholic Acid (UDCA), Obeticholic Acid (Ocaliva)

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Biliary Cholangitis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Ursodeoxycholic Acid (UDCA)
1.2.3 Obeticholic Acid (Ocaliva)
1.3 Market by Application
1.3.1 Global Primary Biliary Cholangitis Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Biliary Cholangitis Treatment Market Perspective (2020-2031)
2.2 Global Primary Biliary Cholangitis Treatment Growth Trends by Region
2.2.1 Global Primary Biliary Cholangitis Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Primary Biliary Cholangitis Treatment Historic Market Size by Region (2020-2025)
2.2.3 Primary Biliary Cholangitis Treatment Forecasted Market Size by Region (2026-2031)
2.3 Primary Biliary Cholangitis Treatment Market Dynamics
2.3.1 Primary Biliary Cholangitis Treatment Industry Trends
2.3.2 Primary Biliary Cholangitis Treatment Market Drivers
2.3.3 Primary Biliary Cholangitis Treatment Market Challenges
2.3.4 Primary Biliary Cholangitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Biliary Cholangitis Treatment Players by Revenue
3.1.1 Global Top Primary Biliary Cholangitis Treatment Players by Revenue (2020-2025)
3.1.2 Global Primary Biliary Cholangitis Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Primary Biliary Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Primary Biliary Cholangitis Treatment Revenue
3.4 Global Primary Biliary Cholangitis Treatment Market Concentration Ratio
3.4.1 Global Primary Biliary Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Biliary Cholangitis Treatment Revenue in 2024
3.5 Global Key Players of Primary Biliary Cholangitis Treatment Head office and Area Served
3.6 Global Key Players of Primary Biliary Cholangitis Treatment, Product and Application
3.7 Global Key Players of Primary Biliary Cholangitis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Biliary Cholangitis Treatment Breakdown Data by Type
4.1 Global Primary Biliary Cholangitis Treatment Historic Market Size by Type (2020-2025)
4.2 Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Type (2026-2031)
5 Primary Biliary Cholangitis Treatment Breakdown Data by Application
5.1 Global Primary Biliary Cholangitis Treatment Historic Market Size by Application (2020-2025)
5.2 Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Primary Biliary Cholangitis Treatment Market Size (2020-2031)
6.2 North America Primary Biliary Cholangitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Primary Biliary Cholangitis Treatment Market Size by Country (2020-2025)
6.4 North America Primary Biliary Cholangitis Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Biliary Cholangitis Treatment Market Size (2020-2031)
7.2 Europe Primary Biliary Cholangitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Primary Biliary Cholangitis Treatment Market Size by Country (2020-2025)
7.4 Europe Primary Biliary Cholangitis Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Biliary Cholangitis Treatment Market Size (2020-2031)
8.2 Asia-Pacific Primary Biliary Cholangitis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Primary Biliary Cholangitis Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Primary Biliary Cholangitis Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Biliary Cholangitis Treatment Market Size (2020-2031)
9.2 Latin America Primary Biliary Cholangitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Primary Biliary Cholangitis Treatment Market Size by Country (2020-2025)
9.4 Latin America Primary Biliary Cholangitis Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size (2020-2031)
10.2 Middle East & Africa Primary Biliary Cholangitis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Primary Biliary Cholangitis Treatment Introduction
11.1.4 Novartis Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025)
11.1.5 Novartis Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Introduction
11.2.4 Bristol-Myers Squibb Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Primary Biliary Cholangitis Treatment Introduction
11.3.4 Pfizer Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025)
11.3.5 Pfizer Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Primary Biliary Cholangitis Treatment Introduction
11.4.4 GlaxoSmithKline Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025)
11.4.5 GlaxoSmithKline Recent Development
11.5 Teva Pharmaceutical
11.5.1 Teva Pharmaceutical Company Details
11.5.2 Teva Pharmaceutical Business Overview
11.5.3 Teva Pharmaceutical Primary Biliary Cholangitis Treatment Introduction
11.5.4 Teva Pharmaceutical Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025)
11.5.5 Teva Pharmaceutical Recent Development
11.6 Retrophin
11.6.1 Retrophin Company Details
11.6.2 Retrophin Business Overview
11.6.3 Retrophin Primary Biliary Cholangitis Treatment Introduction
11.6.4 Retrophin Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025)
11.6.5 Retrophin Recent Development
11.7 Lumena Pharmaceuticals
11.7.1 Lumena Pharmaceuticals Company Details
11.7.2 Lumena Pharmaceuticals Business Overview
11.7.3 Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Introduction
11.7.4 Lumena Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025)
11.7.5 Lumena Pharmaceuticals Recent Development
11.8 Intercept Pharmaceuticals
11.8.1 Intercept Pharmaceuticals Company Details
11.8.2 Intercept Pharmaceuticals Business Overview
11.8.3 Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Introduction
11.8.4 Intercept Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025)
11.8.5 Intercept Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Novartis
Bristol–Myers Squibb
Pfizer Inc
GlaxoSmithKline PLC
Teva Pharmaceutical
Retrophin
Lumena Pharmaceuticals
Intercept Pharmaceuticals
List of Tables
 Table 1. Global Primary Biliary Cholangitis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Ursodeoxycholic Acid (UDCA)
 Table 3. Key Players of Obeticholic Acid (Ocaliva)
 Table 4. Global Primary Biliary Cholangitis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Primary Biliary Cholangitis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Primary Biliary Cholangitis Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Primary Biliary Cholangitis Treatment Market Share by Region (2020-2025)
 Table 8. Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Primary Biliary Cholangitis Treatment Market Share by Region (2026-2031)
 Table 10. Primary Biliary Cholangitis Treatment Market Trends
 Table 11. Primary Biliary Cholangitis Treatment Market Drivers
 Table 12. Primary Biliary Cholangitis Treatment Market Challenges
 Table 13. Primary Biliary Cholangitis Treatment Market Restraints
 Table 14. Global Primary Biliary Cholangitis Treatment Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Primary Biliary Cholangitis Treatment Market Share by Players (2020-2025)
 Table 16. Global Top Primary Biliary Cholangitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Biliary Cholangitis Treatment as of 2024)
 Table 17. Ranking of Global Top Primary Biliary Cholangitis Treatment Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Primary Biliary Cholangitis Treatment Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Primary Biliary Cholangitis Treatment, Headquarters and Area Served
 Table 20. Global Key Players of Primary Biliary Cholangitis Treatment, Product and Application
 Table 21. Global Key Players of Primary Biliary Cholangitis Treatment, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Primary Biliary Cholangitis Treatment Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Type (2020-2025)
 Table 25. Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Type (2026-2031)
 Table 27. Global Primary Biliary Cholangitis Treatment Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Application (2020-2025)
 Table 29. Global Primary Biliary Cholangitis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Primary Biliary Cholangitis Treatment Revenue Market Share by Application (2026-2031)
 Table 31. North America Primary Biliary Cholangitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Primary Biliary Cholangitis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Primary Biliary Cholangitis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Primary Biliary Cholangitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Primary Biliary Cholangitis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Primary Biliary Cholangitis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Primary Biliary Cholangitis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Primary Biliary Cholangitis Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Primary Biliary Cholangitis Treatment Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Primary Biliary Cholangitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Primary Biliary Cholangitis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Primary Biliary Cholangitis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Primary Biliary Cholangitis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Novartis Company Details
 Table 47. Novartis Business Overview
 Table 48. Novartis Primary Biliary Cholangitis Treatment Product
 Table 49. Novartis Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025) & (US$ Million)
 Table 50. Novartis Recent Development
 Table 51. Bristol-Myers Squibb Company Details
 Table 52. Bristol-Myers Squibb Business Overview
 Table 53. Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Product
 Table 54. Bristol-Myers Squibb Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025) & (US$ Million)
 Table 55. Bristol-Myers Squibb Recent Development
 Table 56. Pfizer Company Details
 Table 57. Pfizer Business Overview
 Table 58. Pfizer Primary Biliary Cholangitis Treatment Product
 Table 59. Pfizer Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025) & (US$ Million)
 Table 60. Pfizer Recent Development
 Table 61. GlaxoSmithKline Company Details
 Table 62. GlaxoSmithKline Business Overview
 Table 63. GlaxoSmithKline Primary Biliary Cholangitis Treatment Product
 Table 64. GlaxoSmithKline Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025) & (US$ Million)
 Table 65. GlaxoSmithKline Recent Development
 Table 66. Teva Pharmaceutical Company Details
 Table 67. Teva Pharmaceutical Business Overview
 Table 68. Teva Pharmaceutical Primary Biliary Cholangitis Treatment Product
 Table 69. Teva Pharmaceutical Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025) & (US$ Million)
 Table 70. Teva Pharmaceutical Recent Development
 Table 71. Retrophin Company Details
 Table 72. Retrophin Business Overview
 Table 73. Retrophin Primary Biliary Cholangitis Treatment Product
 Table 74. Retrophin Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025) & (US$ Million)
 Table 75. Retrophin Recent Development
 Table 76. Lumena Pharmaceuticals Company Details
 Table 77. Lumena Pharmaceuticals Business Overview
 Table 78. Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Product
 Table 79. Lumena Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025) & (US$ Million)
 Table 80. Lumena Pharmaceuticals Recent Development
 Table 81. Intercept Pharmaceuticals Company Details
 Table 82. Intercept Pharmaceuticals Business Overview
 Table 83. Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Product
 Table 84. Intercept Pharmaceuticals Revenue in Primary Biliary Cholangitis Treatment Business (2020-2025) & (US$ Million)
 Table 85. Intercept Pharmaceuticals Recent Development
 Table 86. Research Programs/Design for This Report
 Table 87. Key Data Information from Secondary Sources
 Table 88. Key Data Information from Primary Sources
 Table 89. Authors List of This Report


List of Figures
 Figure 1. Primary Biliary Cholangitis Treatment Picture
 Figure 2. Global Primary Biliary Cholangitis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Primary Biliary Cholangitis Treatment Market Share by Type: 2024 VS 2031
 Figure 4. Ursodeoxycholic Acid (UDCA) Features
 Figure 5. Obeticholic Acid (Ocaliva) Features
 Figure 6. Global Primary Biliary Cholangitis Treatment Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Primary Biliary Cholangitis Treatment Market Share by Application: 2024 VS 2031
 Figure 8. Hospitals Case Studies
 Figure 9. Clinics Case Studies
 Figure 10. Others Case Studies
 Figure 11. Primary Biliary Cholangitis Treatment Report Years Considered
 Figure 12. Global Primary Biliary Cholangitis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Primary Biliary Cholangitis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Primary Biliary Cholangitis Treatment Market Share by Region: 2024 VS 2031
 Figure 15. Global Primary Biliary Cholangitis Treatment Market Share by Players in 2024
 Figure 16. Global Top Primary Biliary Cholangitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Biliary Cholangitis Treatment as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Primary Biliary Cholangitis Treatment Revenue in 2024
 Figure 18. North America Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Primary Biliary Cholangitis Treatment Market Share by Country (2020-2031)
 Figure 20. United States Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Primary Biliary Cholangitis Treatment Market Share by Country (2020-2031)
 Figure 24. Germany Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Primary Biliary Cholangitis Treatment Market Share by Region (2020-2031)
 Figure 32. China Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Primary Biliary Cholangitis Treatment Market Share by Country (2020-2031)
 Figure 40. Mexico Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Primary Biliary Cholangitis Treatment Market Share by Country (2020-2031)
 Figure 44. Turkey Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Primary Biliary Cholangitis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Novartis Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2020-2025)
 Figure 48. Bristol-Myers Squibb Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2020-2025)
 Figure 49. Pfizer Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2020-2025)
 Figure 50. GlaxoSmithKline Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2020-2025)
 Figure 51. Teva Pharmaceutical Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2020-2025)
 Figure 52. Retrophin Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2020-2025)
 Figure 53. Lumena Pharmaceuticals Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2020-2025)
 Figure 54. Intercept Pharmaceuticals Revenue Growth Rate in Primary Biliary Cholangitis Treatment Business (2020-2025)
 Figure 55. Bottom-up and Top-down Approaches for This Report
 Figure 56. Data Triangulation
 Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Primary Biliary Cholangitis Therapeutics Market Insights Forecast to 2030
Global Primary Sclerosing Cholangitis Treatment Market Insights Forecast to 2030
Global Primary Sclerosing Cholangitis PSC Market Research Report 2024
Global Primary Biliary Cirrhosis Drug Market Research Report 2024
Global Biliary Tract Disorder Treatment Market Insights Forecast to 2030
Global Ursodeoxycholic Acid Drug Market Research Report 2024
Global Byler Disease Treatment Market Research Report 2024
Global Bile Duct Cancer Therapeutics Market Insights Forecast to 2030
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biliary Tumor Market Insights Forecast to 2030
Global Bile Duct Cancer Drugs Market Insights Forecast to 2030
Global Autoimmune Hepatitis Treatment Market Insights Forecast to 2030
Global FDF of UDCA and t UDCA Market Research Report 2025
Bile Duct Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs of UDCA and t UDCA Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Biliary Tract Cancers BTCs Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cardiac Cirrhosis Treatment Market Research Report 2024
Global Biliary Atresia Treatment Market Research Report 2024
Global Hyodeoxycholic Acid Market Research Report 2025
Global Choledocholithiasis Treatment Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Chronic Pain Medical Devices Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0I20198
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Disposable Insulin Pen Needle Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33W11115
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32E19705
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions